MNOV Profile
MediciNova, Inc., a dynamic biopharmaceutical firm based in La Jolla, California, is dedicated to pioneering novel small molecule therapeutics to address critical medical conditions with significant unmet needs across the United States. Established in 2000, the company focuses on developing innovative treatments that span a spectrum of serious diseases.
Central to MediciNova's pipeline is MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent under development for various neurological disorders. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, glioblastoma, and substance dependence and addiction.
In addition to MN-166, the company's diverse portfolio includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at managing acute exacerbations of asthma. MediciNova also advances MN-001 (tipelukast), an orally bioavailable small molecule compound targeting fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Further enhancing its oncology offerings, the company develops MN-029 (denibulin), a potent tubulin binding agent designed for treating solid tumor cancers.
MediciNova thrives on strategic collaborations to bolster its research and development efforts. Partnerships with industry leaders like Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. underscore its commitment to advancing therapeutic solutions. With a robust pipeline and a steadfast commitment to innovation, MediciNova remains at the forefront of biopharmaceutical innovation, poised to make meaningful contributions to patient care and medical advancement.
|
